Activity of crizotinib over choroidal metastases in Non-Small-Cell Lung Cancer (NSCLC)-ALK rearranged: a case report

BACKGROUND: Adenocarcinoma of the lung with EML4-ALK translocation is a rare subtype of Non Small-Cell Lung Cancer (NSCLC) that has recently shown to benefit from treatment with crizotinib. Despite the concerns about the efficacy of crizotinib over cerebral metastases, some reports have described it...

Descripción completa

Detalles Bibliográficos
Autores principales: Bearz, Alessandra, Santarossa, Sandra, Manfrè, Antonio, Beltrame, Giorgio, Urbani, Martina, Sartor, Ivana, Da Ros, Valentina, Tirelli, Umberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167132/
https://www.ncbi.nlm.nih.gov/pubmed/25178493
http://dx.doi.org/10.1186/1756-0500-7-589
Descripción
Sumario:BACKGROUND: Adenocarcinoma of the lung with EML4-ALK translocation is a rare subtype of Non Small-Cell Lung Cancer (NSCLC) that has recently shown to benefit from treatment with crizotinib. Despite the concerns about the efficacy of crizotinib over cerebral metastases, some reports have described its activity, although always after local treatment with radiotherapy. Recently it has been reported activity of crizotinib over choroidal metastases, again after radiotherapy. CASE PRESENTATION: Herein we report a case of activity of crizotinib over choroidal metastases not previously treated with radiotherapy. CONCLUSION: We suggest crizotinib may be active over choroidal metastases in a patient harboring ALK translocation with no need of radiotherapy.

Ejemplares similares